Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 22;18:17448069221094528. doi: 10.1177/17448069221094528

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© © The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — The AKT agonist 740Y-P inhibited the effect of sFlt1. The PWMT of the 740 Y-P- and sFlt1-treated mice at different time points (n = 6). The paw withdrawal threshold was significantly reduced on 3rd to 14th day after SNI (red curve) when compared to sham group, sFlt1 ameliorate the reduced PWMT from 5th to 14th day (green curve); 740Y-P reversed the sFlt1 improved PWMT (blue curve).The data are shown as the mean ± SEM (n = 3). The results were analyzed by One-way analysis of variance ANOVA and by multiple comparisons, 740 Y-P versus sFlt1. ⁎ p < .05, ⁎⁎ p < .01, and ⁎⁎⁎ p < .001.